Synthesis, Anti-Cancer Evaluation and In Vitro Study of Some Novel Pyr- rolo-Pyrimidine Scaffolds | ||||
| Egyptian Journal of Chemistry | ||||
| Volume 68, Issue 9, September 2025, Page 553-564 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejchem.2025.340559.10906 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mariem El Saeed Mohamed  1; Samar S. Fatahala 2; Hanaa B Atya3; Rania Helmy Abd El-Hameed4; Amira Ibrahim Sayed5; Omnia Aly6; Mosaad Sayed Mohamed7
| ||||
| 1Pharmaceutical organic chemistry , faculty of pharmacy , helwan university, cairo,egypt | ||||
| 2Pharmaceutical Organic Chemistry Department, Faculty of pharmacy, Helwan University | ||||
| 3Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, , Cairo, Egypt. | ||||
| 4Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain Helwan, Helwan, Egypt. | ||||
| 5Faculty of pharmacy, Ahram Canadian University, 6th-October, Giza, Egypt | ||||
| 6Medical Biochemistry Department, National Research Centre, Dokki, Cairo, Egypt | ||||
| 71Pharmaceutical Organic Chemistry Department, Faculty of pharmacy, Helwan University | ||||
| Abstract | ||||
| Following their synthesis in good to medium yields, pyrrole-pyrimidine-5-cyano scaffolds (2 and 4) were tested for anti-cancer efficacy using the MTT assay against ovarian cancer (SKOV-3) and breast cancer (MCF-7) cell lines. The IC50 values of 1031.135 µg/mL and 846.4994 μg/mL, respectively, were obtained from cytotoxicity assays conducted on the SKOV-3 and MCF-7 cell lines, which demonstrated a substantial decrease in cell viability. Apoptosis and Cell cycle arrest were also carried out to configure the primary contact with cancer cell lines, and N-pyrrole-pyrimidine-5-cyano 2a demonstrated the most anti-cancer efficacy against both tested cell lines in the in vitro assay. Additionally, the molecular docking research revealed that compound (2a) interacts significantly with active sites of Cyclin-dependent kinase 2 (CDK-2) (PDB: 5ANJ) and Cyclin-dependent kinase 6 (CDK-6) (PDB: 5LT2). In order to determine the primary method of action, enzymatic assays were also conducted on CDK2 and CDK6 utilizing specialized Enzyme-Linked Immunosorbent Assay (ELISA) Kits. Our findings indicated that compound (2a) has the potential to be an effective cancer treatment. | ||||
| Keywords | ||||
| CDK-2; CDK-6; anti-cancer; pyrimidine; pyrrole | ||||
|
Statistics Article View: 217 |
||||
